J. Fraser Wright, PhD
Professor of Pediatrics, CDCM
Dr. Wright received his PhD from the University of Toronto (Biochemistry) and completed his post-doctoral fellowship at INSERM / CENG Grenoble, France. He was awarded a Canadian Red Cross Society / Medical Research Council Scholarship in 1993, gaining an Assistant Professor position at the University of Toronto. In 1996, he joined industry as a Scientist at Pasteur Sanofi working towards the development of cancer immunotherapies, and subsequently as Director of Development and Clinical Manufacturing at Avigen, a gene therapy company that pioneered AAV-based investigational gene therapies for hemophilia and Parkinson’s Diseases. In 2004, he returned to academia, establishing the Clinical Vector Core at the Center for Cellular and Molecular Therapeutics at Children’s Hospital of Philadelphia, and he was appointed as Professor of Pathology and Laboratory Medicine at the University of Pennsylvania Perelman School of Medicine. He is a co-founder of Spark Therapeutics, where he worked for four years as the Chief Technology Officer and recently, he served as Chief Technology Officer at Axovant.
Dr. Wright is an internationally recognized leader in the field of gene therapy, he has contributed to the development of several gene therapy products, including Kymriah (CAR-T immunotherapy) and Luxturna, the first therapy for a genetic blindness (RPE65 deficiency), recently approved in the United States.
Dr. Wright joins Stanford University as Professor of Pediatrics at the CDCM. His research program aims to address key immunological barriers to gene therapy through innovative approaches to viral vector design and generation, and to develop vectorized antibodies for serious human diseases. Dr. Wright will contribute expertise in vectorology, translational research, and clinical manufacturing and quality systems towards successful development of transformative stem cell and gene therapies discovered at the CDCM and the Institute for Stem Cell Biology and Regenerative Medicine.